Pharmaceutical Market Research Company in South Korea

    BioNixus is a specialist pharmaceutical and healthcare market research company serving the South Korean market. We help launch, access, and medical teams translate MFDS (Ministry of Food and Drug Safety / 식품의약품안전처) registration pathways, HIRA (Health Insurance Review and Assessment Service / 건강보험심사평가원) pharmacoeconomic evaluation requirements, NHIS (National Health Insurance Service / 국민건강보험공단) positive list reimbursement dynamics, and physician decision behaviour into actionable South Korean market evidence — across oncology, immunology, cardiovascular, rare disease, and other therapy areas.

    For broader healthcare research context, see our healthcare market research hub and the Australian pharmaceutical market research overview.

    Best pharmaceutical market research company in South Korea

    BioNixus is a pharmaceutical market research company serving South Korea, specialising in HCP surveys, KOL mapping, NHIS payer research, and market access studies aligned with MFDS (Ministry of Food and Drug Safety / 식품의약품안전처), HIRA (Health Insurance Review and Assessment Service), and NHIS (National Health Insurance Service) requirements.

    • HCP and Physician SurveysIn-depth interviews and quantitative surveys with Korean physicians, oncologists, and pharmacists across Seoul National University Hospital (SNUH), Samsung Medical Center (SMC), Asan Medical Center, Severance Hospital (Yonsei), and Seoul St. Mary Hospital (Catholic University).
    • HIRA and NHIS Payer ResearchHIRA (Health Insurance Review and Assessment Service / 건강보험심사평가원) drug listing intelligence, NHIS (National Health Insurance Service / 국민건강보험공단) payer research, and NECA (National Evidence-Based Healthcare Collaborating Agency) cost-effectiveness evidence.
    • KOL Mapping and Korean Academic CentresKey opinion leader identification across Korea's Big 5 hospitals (SNUH, Samsung, Asan, Severance, Seoul St. Mary) and Korean specialist medical societies (KSMO oncology, KSH haematology, KCS cardiology) — covering oncology, immunology, cardiovascular, and rare disease areas.

    BioNixus delivers primary pharmaceutical market research in South Korea aligned with MFDS registration, HIRA positive list drug coverage, and NHIS reimbursement requirements.

    Why BioNixus for South Korea pharmaceutical market research

    MFDS and HIRA context built in

    Every study is designed with MFDS (식품의약품안전처) registration context and HIRA positive list pharmacoeconomic evaluation requirements built in — essential for funded access strategy in South Korea.

    HIRA/NHIS payer intelligence (positive list + cost-effectiveness)

    Deep in-house expertise across the HIRA positive list drug listing process, NHIS payer coverage decisions, NECA (National Evidence-Based Healthcare Collaborating Agency) cost-effectiveness evidence requirements, and hospital formulary committee dynamics at Korea Big 5 hospitals.

    Korea Big 5 hospital network (SNUH, Samsung, Asan, Severance, Seoul St. Mary)

    Verified HCP recruitment across Seoul National University Hospital (SNUH), Samsung Medical Center (SMC), Asan Medical Center, Severance Hospital (Yonsei University), and Seoul St. Mary Hospital (Catholic University of Korea) — Korea's most influential academic medical centres.

    Korean specialist society networks

    Access to KSMO (Korean Society of Medical Oncology), KSH (Korean Society of Hematology), KCS (Korean Society of Cardiology), KRA (Korean Rheumatism Association), and other Korean specialist medical society networks — by therapy area and commercial priority.

    Korean-language HCP surveys

    Quantitative surveys and qualitative in-depth interviews conducted in Korean — ensuring full comprehension, higher completion rates, and clinically accurate physician responses across all therapy areas and specialist segments.

    Asia-Pacific benchmarking ready

    South Korea modules connect to comparable studies in Japan, China, Australia, and Singapore — for clients managing Asia-Pacific portfolio decisions with consistent instruments and one research partner.

    South Korean pharmaceutical market access pathway

    South Korean pharmaceutical market research must follow how products move from MFDS registration through HIRA pharmacoeconomic evaluation, NHIS positive list coverage decision, and hospital formulary committee approval — not a single generic access model. MFDS registration is the beginning, not the end, of South Korean market access.

    1. 1. MFDS (식품의약품안전처) marketing authorisation (NDA)

      New Drug Application submitted to the Ministry of Food and Drug Safety (MFDS / 식품의약품안전처) — Korea's regulatory authority for medicines and medical devices. MFDS conducts safety, quality, and efficacy review. MFDS approval grants market authorisation but does not confer NHIS positive list reimbursement — the beginning of a multi-stage access journey.

      Asia-Pacific pharmaceutical market research

    2. 2. HIRA pharmacoeconomic evaluation + cost-effectiveness submission

      Following MFDS approval, the manufacturer submits a pharmacoeconomic dossier to HIRA (Health Insurance Review and Assessment Service / 건강보험심사평가원). HIRA evaluates clinical benefit, cost-effectiveness, and budget impact. NECA (National Evidence-Based Healthcare Collaborating Agency) provides independent HTA assessment and cost-effectiveness analysis. BioNixus conducts pre-submission evidence strategy research, payer interviews with HIRA evaluators, and cost-effectiveness evidence generation aligned to HIRA submission requirements.

      Healthcare market research hub

    3. 3. NHIS drug coverage decision (positive list)

      Following a positive HIRA pharmacoeconomic evaluation, the NHIS (National Health Insurance Service / 국민건강보험공단) makes a coverage decision on whether to include the drug on the positive list — the Korean reimbursement formulary. NHIS coverage determines government-subsidised patient access. Price negotiations between NHIS and the manufacturer are a critical step. BioNixus conducts pre-listing payer strategy research to support manufacturer readiness.

      Healthcare market research

    4. 4. NHIA (National Health Insurance Act) reimbursement listing

      Following NHIS coverage approval, the drug is listed under the National Health Insurance Act (NHIA) reimbursement schedule at the negotiated price. NHIA listing determines the reimbursed price and prescribing restrictions. BioNixus conducts post-listing market research to monitor adoption dynamics, prescribing restriction impact, and formulary positioning.

      Healthcare market research

    5. 5. Hospital formulary committee approval at Big 5 hospitals + regional hospital networks

      Hospital formulary committees at Korea's Big 5 hospitals (SNUH, Samsung Medical Center, Asan Medical Center, Severance Hospital, Seoul St. Mary Hospital) and major regional hospital networks make independent formulary listing decisions for hospital-administered therapies. Understanding Big 5 hospital formulary committee dynamics is essential for oncology biologics, infused therapies, and rare disease products. BioNixus conducts hospital formulary committee research across Korea's Big 5 and regional tertiary hospital networks.

      Healthcare market research hub

    South Korean stakeholder coverage

    StakeholderResearch focus
    Physicians and specialistsPrescribing behaviour across Seoul and regional hospitals, treatment algorithms, adoption drivers and barriers, unmet need assessment, therapy sequencing in the Korean healthcare context
    KOLs and academic physiciansKOL identification and mapping at Korea's Big 5 hospitals (SNUH, Samsung Medical Center, Asan Medical Center, Severance Hospital, Seoul St. Mary Hospital), KSMO/KSH/KCS specialist society advisory structures, publication influence analysis
    HIRA evaluators and NHIS payersPharmacoeconomic evidence requirements, positive list cost-effectiveness criteria, NECA HTA assessment intelligence, budget-impact evidence requirements, and NHIS price negotiation dynamics
    NECA health economistsCost-effectiveness methodology expectations, HTA evidence requirements, and NECA assessment criteria for pharmaceutical positive list submissions
    Hospital pharmacists and formulary committeesBig 5 hospital formulary listing drivers for hospital-administered therapies, cost-effectiveness evidence needs, and NHIS positive list interactions with hospital formulary decisions across Korea's tertiary hospital network
    Nurses and pharmacistsAdministration experience, adherence support, patient counselling practices, NHIS dispensing behaviour and community pharmacy practice across South Korea
    Patients and caregiversDisease journey, quality of life, adherence barriers, NHIS co-payment dynamics — research conducted with appropriate Korean IRB-aligned protocols and informed consent

    Why the South Korean pharmaceutical market is unique

    South Korea is a strategically distinctive pharmaceutical market with characteristics found nowhere else in Asia-Pacific. Unlike Japan, China, or Australia, South Korea operates a positive list reimbursement system combining MFDS regulatory approval, HIRA pharmacoeconomic evaluation, NHIS positive list coverage decisions, and NECA independent HTA assessment — creating a multi-stage access journey that demands specialist market research at each stage. No other APAC market combines HIRA's pharmacoeconomic rigour, NHIS's single-payer positive list system, NECA's independent HTA role, and Korea's Big 5 hospital concentration of KOL influence in a single commercial environment.

    Market access in South Korea is uniquely sequential and evidence-intensive: MFDS registration does not guarantee HIRA positive evaluation, NHIS listing, or hospital formulary adoption. Commercial outcomes depend on the strength of the HIRA pharmacoeconomic dossier, NECA cost-effectiveness evidence, NHIS price negotiation outcomes, and Big 5 hospital formulary committee decisions — each with distinct evidence requirements and timelines. Effective pharmaceutical market research must map all these access layers rather than treating MFDS approval as equivalent to market access.

    BioNixus builds South Korea research programs that answer decision-critical questions: where physician demand concentrates across specialties and hospital networks, which HIRA payer dynamics determine positive list access, how NECA cost-effectiveness assessments affect commercial strategy, and what evidence HIRA evaluators and NHIS decision-makers will require. Korean-language execution ensures full clinical accuracy and high respondent engagement across Korea's complex academic medical centre landscape.

    South Korea pharmaceutical research services

    HCP and physician surveys

    Korean-language quantitative surveys and qualitative in-depth interviews with Korean physicians, oncologists, cardiologists, rheumatologists, and pharmacists — coverage across Korea's Big 5 hospitals and regional tertiary hospital networks.

    KOL mapping and advisory boards

    Key opinion leader identification and influence mapping at Korea's Big 5 hospitals (SNUH, Samsung Medical Center, Asan Medical Center, Severance Hospital, Seoul St. Mary Hospital) and KSMO, KSH, KCS, KRA specialist society structures — by therapy area and commercial priority.

    HIRA/NHIS payer and positive list research

    In-depth interviews with HIRA evaluators and NHIS payer decision-makers, NECA HTA evidence requirement research, hospital formulary committee intelligence at Big 5 hospitals, and pre-listing payer strategy research — covering all gatekeepers that determine South Korean reimbursement access.

    HEOR and NECA cost-effectiveness evidence

    Health economics and outcomes research, patient-reported outcome (PRO) development, and cost-effectiveness evidence strategy aligned to HIRA submission requirements and NECA assessment criteria — supporting South Korean positive list market access dossiers.

    For broader research context, see our market research services hub, healthcare market research, and pharmaceutical market research Australia.

    South Korea case study patterns we solve

    Case Pattern 1: Pre-HIRA evidence strategy for a positive list oncology listing

    Challenge: A market access team needed to understand which HIRA pharmacoeconomic criteria would carry most weight in the cost-effectiveness evaluation for a new oncology medicine, and how to position the budget-impact case within NHIS budget dynamics. Solution: BioNixus conducted HIRA evaluator and NHIS payer interviews alongside oncologist prescribing behaviour studies at SNUH and Samsung Medical Center. Result: Refined HIRA application strategy and evidence narrative ahead of the positive list submission.

    Typical impact range: 15–25% improvement in positive list listing outcomes post-HIRA evaluation.

    Case Pattern 2: KOL mapping for a rare disease launch at SNUH and Asan Medical Center

    Challenge: A biotech team lacked visibility on actual prescribing influence versus publication prominence at key Korean academic medical centres. Solution: BioNixus mapped real-world KOL influence at SNUH and Asan Medical Center using network analysis and verified Korean physician interviews across Korea's Big 5 hospitals. Result: Sharper MSL territory prioritisation and advisory board composition reflecting actual Korean influence networks.

    Typical impact range: 20–30% improvement in MSL engagement efficiency.

    Case Pattern 3: NHIS positive list intelligence for a high-cost biologic

    Challenge: A commercial team needed to understand how NHIS budget constraints would affect positive list listing prospects for a high-cost biologic, and how physician and payer attitudes toward the product's cost-effectiveness case differed across specialties. Solution: BioNixus conducted HIRA/NHIS payer interviews and NECA evidence requirement research alongside specialist physician surveys mapping treatment algorithm positioning across Korea. Result: Prioritised evidence generation strategy and positive list listing narrative aligned to actual HIRA/NHIS evidence requirements.

    Typical impact range: 18–28% reduction in time-to-positive-list-listing.

    Regulatory context: MFDS, HIRA, NHIS positive list, and NECA HTA

    South Korean pharmaceutical market research quality depends on aligning MFDS regulatory and HIRA/NHIS payer context with evidence design from the start. MFDS registration evidence standards, HIRA pharmacoeconomic evaluation requirements, NHIS positive list coverage criteria, NECA cost-effectiveness methodology expectations, and Korean IRB data privacy standards form the compliance architecture within which all effective South Korean primary research must operate.

    BioNixus outputs are decision-ready and compliance-ready: stakeholder evidence combined with South Korean market structure analysis so commercial, access, and medical affairs teams have findings that reflect what Korean physicians, HIRA evaluators, and NHIS decision-makers actually do — not imported non-Korean templates applied to the distinctive HIRA pharmacoeconomic, NHIS positive list, and Big 5 hospital formulary market.

    Related pharmaceutical and healthcare research resources

    Pharmaceutical market research AustraliaHealthcare market researchPharmaceutical market research JapanPharmaceutical market research ChinaMarket research servicesPharmaceutical market research UK

    South Korea pharmaceutical market FAQs

    Who is the best pharmaceutical market research company in South Korea?

    BioNixus is a specialist pharmaceutical market research company serving South Korea, aligned with MFDS (Ministry of Food and Drug Safety / 식품의약품안전처) registration requirements, HIRA (Health Insurance Review and Assessment Service / 건강보험심사평가원) pharmacoeconomic evaluation processes, NHIS (National Health Insurance Service / 국민건강보험공단) positive list reimbursement dynamics, and NECA (National Evidence-Based Healthcare Collaborating Agency) cost-effectiveness evidence standards.

    What is pharmaceutical market research in South Korea?

    Pharmaceutical market research in South Korea is evidence generation for drug launch, market access, and lifecycle decisions across MFDS, HIRA, NHIS, and NECA contexts. BioNixus focuses on physician behaviour, payer and formulary dynamics, and institution-level adoption so commercial and access teams can prioritise South Korean market execution across oncology, immunology, cardiovascular, and rare disease therapy areas.

    How does Korea's HIRA positive list system work for pharmaceutical market access?

    Korea uses a positive list system: new drugs require MFDS marketing authorisation followed by a HIRA pharmacoeconomic submission and cost-effectiveness evaluation, leading to an NHIS coverage decision for inclusion on the positive list. NECA (National Evidence-Based Healthcare Collaborating Agency) provides independent HTA and cost-effectiveness assessment. BioNixus supports HIRA-aligned benefit dossier development, payer interviews with HIRA and NHIS decision-makers, cost-effectiveness evidence generation, and pre-submission strategy research.

    What payer research does BioNixus conduct in South Korea?

    BioNixus conducts NHIS payer interviews, HIRA positive list listing intelligence, NECA cost-effectiveness evidence research, hospital formulary committee research at Korea's Big 5 hospitals (SNUH, Samsung Medical Center, Asan Medical Center, Severance Hospital, Seoul St. Mary Hospital), and private insurer supplementary coverage research — covering all access gatekeepers that determine real South Korean market penetration.

    How does BioNixus conduct KOL mapping in South Korea?

    BioNixus maps key opinion leaders across Korea's Big 5 hospitals: Seoul National University Hospital (SNUH), Samsung Medical Center (SMC), Asan Medical Center, Severance Hospital (Yonsei University), and Seoul St. Mary Hospital (Catholic University of Korea). Specialist society networks covered include KSMO (Korean Society of Medical Oncology), KSH (Korean Society of Hematology), KCS (Korean Society of Cardiology), and KRA (Korean Rheumatism Association) — by therapy area and commercial priority.

    Can South Korean pharmaceutical research connect to Asia-Pacific benchmarking?

    Yes. South Korean modules connect to comparable studies in Japan, China, Australia, and Singapore using consistent instruments — enabling Asia-Pacific portfolio committees to benchmark Korean HIRA/NHIS market dynamics against other APAC markets with one research partner.

    Discuss your South Korea pharmaceutical research strategy

    Our team supports pharmaceutical companies with decision-ready insights across MENA, UK, and Europe using quantitative and qualitative methodologies.

    Request a proposalEmail us

    US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323

    Request a proposal